BIOL.Q Stock Overview Develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. More details
Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
BIOLASE, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for BIOLASE Historical stock prices Current Share Price US$0.012 52 Week High US$1.19 52 Week Low US$0.004 Beta 0.92 1 Month Change 87.50% 3 Month Change -30.84% 1 Year Change -98.91% 3 Year Change -100.00% 5 Year Change -100.00% Change since IPO -100.00%
Recent News & Updates Motion for Joint Administration Approved for BIOLASE, Inc. Oct 03
BIOLASE, Inc. Filed for Bankruptcy The Nasdaq Stock Market to Delist Common Stock of BIOLASE Sep 06
BIOLASE, Inc. Provides Earnings Guidance for the Year 2024 Aug 09
BIOLASE, Inc.(OTCPK:BIOL) dropped from NASDAQ Composite Index Jun 20 Nasdaq Hearings Panel Determines to Delist BIOLASE's Common Stock Jun 18
See more updates Motion for Joint Administration Approved for BIOLASE, Inc. Oct 03
BIOLASE, Inc. Filed for Bankruptcy The Nasdaq Stock Market to Delist Common Stock of BIOLASE Sep 06
BIOLASE, Inc. Provides Earnings Guidance for the Year 2024 Aug 09
BIOLASE, Inc.(OTCPK:BIOL) dropped from NASDAQ Composite Index Jun 20 Nasdaq Hearings Panel Determines to Delist BIOLASE's Common Stock Jun 18
Biolase Receives an Additional Staff Determination Letter from Nasdaq Regarding Non-Compliance with Minimum $2.5 Million Stockholders’ Equity Requirement for Continued Listing Set in Nasdaq Listing Rule 5550(b) May 18
BIOLASE, Inc. Reiterates Earnings Guidance for the Full-Year of 2024 May 15
BIOLASE, Inc. to Report Q1, 2024 Results on May 13, 2024 May 08
BIOLASE Receives Staff Determination Letter from Nasdaq Regarding Failure to Meet the Minimum Closing Bid Price Requirement as Required by Listing Rule 5550(a)(2) Apr 21
BIOLASE, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024 Mar 23
BIOLASE, Inc. to Report Q4, 2023 Results on Mar 21, 2024 Mar 15
BIOLASE, Inc., Annual General Meeting, May 02, 2024 Mar 09
BIOLASE Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Mar 05 BIOLASE, Inc. has completed a Composite Units Offering in the amount of $7.031795 million. Feb 16
Nasdaq Grants Extension to BIOLASE, Inc. to Regain Compliance with the Stockholders' Equity Continued Listing Requirement Feb 15
BIOLASE, Inc. Provides Earnings Guidance for the Full-Year 2023 Jan 30
BIOLASE, Inc. Provides Earnings Guidance for the Year 2024 Jan 29
Dr. Carol Gomez Summerhays Intends to Resign as Member of the Board of Directors of Biolase, Inc Dec 30
BIOLASE, Inc. Successfully Concludes Waterlase iPlus All Tissue Laser Trial Dec 13 BIOLASE, Inc. has filed a Follow-on Equity Offering. Dec 07
BIOLASE Receives Non-Compliance Notice From Nasdaq Nov 18
BIOLASE, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2023 Nov 11
BIOLASE, Inc. Announces Study Performed by the Independent Mcguire Institute Confirms Positive 12 Month Clinical Outcomes for Biolase Repair(R) Perio Protocol Nov 09
BIOLASE, Inc. to Report Q3, 2023 Results on Nov 09, 2023 Nov 08 BIOLASE, Inc. has completed a Composite Units Offering in the amount of $4.5 million. Sep 15
BIOLASE Provides Non-Compliance Update Aug 17
BIOLASE, Inc. Provides Earnings Guidance for the Second Half of 2023 Aug 12
BIOLASE, Inc. to Report Q2, 2023 Results on Aug 10, 2023 Aug 03 Listing Qualifications Staff of Nasdaq Determines to Delist BIOLASE's Common Stock from the Nasdaq Capital Market and to Suspend Trading of the Common Stock at the Opening of Business on June 20 2023 Jun 14
BIOLASE, Inc. has completed a Composite Units Offering. May 26
BIOLASE, Inc. has completed a Composite Units Offering. May 25
BIOLASE, Inc. to Report Q1, 2023 Results on May 11, 2023 May 05
BIOLASE, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022 Jan 19
BIOLASE Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market Jan 13 BIOLASE, Inc. has completed a Follow-on Equity Offering in the amount of $9.635963 million. Jan 12
BIOLASE, Inc. has completed a Follow-on Equity Offering in the amount of $9.635963 million. Jan 11
PIPStek LLC Files Patent Infringement Lawsuit Against BIOLASE Jan 05
BIOLASE, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2022 Nov 11
BIOLASE, Inc. to Report Q3, 2022 Results on Nov 10, 2022 Oct 28
BIOLASE, Inc. Appoints Russell Morrow as Chief Dental Officer, Effective November 1, 2022 Oct 14
Biolase partners with dental speciality programs across U.S. Aug 31
BIOLASE, Inc. Provides Revenue Forecast for the Third Quarter Ending September 30, 2022 and Full Year of 2022 Aug 13
BIOLASE, Inc. Provides Revenue Forecast for the Third Quarter Ending September 30, 2022 and Full Year of 2022 Aug 12
BIOLASE, Inc. to Report Q2, 2022 Results on Aug 11, 2022 Jul 29
BIOLASE: Ongoing Operating Losses, Capital Raises To Sustain Liquidity Jul 21 BIOLASE, Inc. Appoints Steven Sandor to Chief Operating Officer
BIOLASE amends senior secured term loan with SWK Funding Jul 01
BIOLASE, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement May 18
BIOLASE, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2022 May 14
First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat May 13
High number of new directors May 10 BIOLASE, Inc. Announces Election of Board of Directors May 10
BIOLASE, Inc. to Report Q1, 2022 Results on May 12, 2022 May 05
BIOLASE: Bad News Across The Board - Sell Mar 21
Price target decreased to US$2.13 Mar 21
Full year 2021 earnings: EPS and revenues exceed analyst expectations Mar 19
Is BIOLASE (NASDAQ:BIOL) Weighed On By Its Debt Load? Feb 24
BIOLASE, Inc. Provides Revenue Guidance for the Fourth Quarter of 2021 Jan 12
BIOLASE - Speculative Buy After Strong Preliminary Q4 Results Jan 11
BIOLASE and EdgeEndo Announce FDA 510(k) Clearance of New EdgePRO Laser-Assisted Microfluidic Irrigation Device for Endodontists Jan 07
BIOLASE - Good News Across The Board But Still Only Suited For The Most Speculative Investors Nov 24
Nasdaq Grants BIOLASE 180-Day Extension to Meet Minimum Bid Price Requirement Nov 24
Third quarter 2021 earnings released: US$0.022 loss per share (vs US$0.21 loss in 3Q 2020) Nov 12
High number of new directors Sep 02
Price target increased to US$2.25 Aug 19
Independent Director Garrett Sato has left the company Aug 18
Independent Director Michael DiTolla has left the company Aug 18
Second quarter 2021 earnings released: US$0.005 loss per share (vs US$0.12 loss in 2Q 2020) Aug 13 Shareholder Returns BIOL.Q US Medical Equipment US Market 7D 60.0% -0.8% -1.1% 1Y -98.9% 8.4% 22.4%
See full shareholder returns
Return vs Market: BIOL.Q underperformed the US Market which returned 22.4% over the past year.
Price Volatility Is BIOL.Q's price volatile compared to industry and market? BIOL.Q volatility BIOL.Q Average Weekly Movement 50.1% Medical Equipment Industry Average Movement 8.0% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.6% 10% least volatile stocks in US Market 3.1%
Stable Share Price: BIOL.Q's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BIOL.Q's weekly volatility has increased from 32% to 50% over the past year.
About the Company BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, hygiene, temporary pain relief, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production.
Show more BIOLASE, Inc. Fundamentals Summary How do BIOLASE's earnings and revenue compare to its market cap? BIOL.Q fundamental statistics Market cap US$402.57k Earnings (TTM ) -US$15.97m Revenue (TTM ) US$46.03m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) BIOL.Q income statement (TTM ) Revenue US$46.03m Cost of Revenue US$30.18m Gross Profit US$15.85m Other Expenses US$31.82m Earnings -US$15.97m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.44 Gross Margin 34.44% Net Profit Margin -34.69% Debt/Equity Ratio -486.1%
How did BIOL.Q perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/31 23:18 End of Day Share Price 2024/12/31 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources BIOLASE, Inc. is covered by 11 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Edward Woo Ascendiant Capital Markets LLC Bruce Jackson Benchmark Company Kyle Bauser Colliers Securities
Show 8 more analysts 
